ZLD secures US$8.6 million funding for HOPE 1 US FDA trials
Filed with ASX · · 7 pages · English
Zelira Therapeutics Ltd. on 6ix
Story so far
Earlier from Zelira Therapeutics
- December 2022 Quarterly Activities Report
- Zelira receives $1.14 million cash R&D Tax Incentive
- ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial
- September 2022 Quarterly Activities Report
- ZLDs Diabetic Nerve Pain Drug Trial Two-Thirds Enrolled
Later from Zelira Therapeutics
- Zelira Executive Director Appointed
- Appendix 4D & FY23 Interim Financial Report
- Zelira raises A$1.77 million from US-based investors
- March 2023 Quarterly Activities Report
- ZLD secures additional US$3.25M investment in HOPE SPV
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics